Study of Disulfiram to Reduce Myeloid Immunosuppression and Steroid Dependence in Resectable High Grade Glioma | MicrobiomeTrials← Back to trialsNCT07719127
Study of Disulfiram to Reduce Myeloid Immunosuppression and Steroid Dependence in Resectable High Grade Glioma
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-10Est. Completion: 2027-12-17
Enrollment target: 20 participants Locations- University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Other microbiome trials you might be interested in
Optic Pathway Glioma
Infantile optic pathway glioma (OPG) is generally benign and slow-growing, but due to infiltration and compression of se…
Rome, ItalyEst. completion Jun 30, 2027
B-cell Mediated Autoimmune Disorders
The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-c…
La Jolla, United StatesEst. completion Dec 1, 2026
Phase 3
Recruiting
Multiple Sclerosis (MS) Primary Progressive
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicente…
Pheonix, United StatesEst. completion Jun 2030